 CARMIEL, Israel, March 30, 2021 PRNewswire -- Protalix BioTherapeutics, Inc. NYSE American: PLX TASE: PLX, a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2020 and provided a business update on recent corporate and clinical developments. 2020 was an important year for Protalix, as we continued to strengthen the clinical profile of PRX102 for the treatment of Fabry disease and advance towards potential commercialization of our lead pipeline program, said Dror Bashan, Protalixs President and Chief Executive Officer. 